NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









InsuLife

InsuLife

Private
OsloHealthcare & Life Scienceshttps://insulife.com/

Last Round

Debt

Apr 24, 2024

Est. Valuation

$26.13M

Total Funding Raised

$3.28M

Company Overview

InsuLife is a drug discovery company developing a transdermal, needle-free insulin and GLP-1 delivery technology designed for the administration of insulin without injections.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Medical Devices

Business Model

B2B2C

Customer Profile

Revenue Share, Hardware + Subscription, Government Contracts

AI Layer

Non-AI

Keywords

needle-free insulininsulin spraytransdermal insulintransdermal drug deliverydiabetes treatmentdrug delivery platformspray-on insulinlipid envelope technologyneedle-free GLP-1transdermal GLP-1pharmaceuticalsbiotechnologyclinical trialspreclinical stagepharma licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

InsuLife Comparables

Compare InsuLife with similar companies based on industry and business-model similarity.

InsuLife comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Biotts
74%
Oramed Pharmaceuticals Inc.
74%
NuGen Medical Devices Inc.
72%

InsuLife Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
DebtApr 24, 2024
Early FundingApr 24, 2024
DebtAug 22, 2023
CrowdfundingOct 13, 2022
AcceleratorAug 25, 2020
Grant
Jun 21, 2020

Key People

Founding team and executive leadership

Åge Nærdal

Chief Executive Officer at Insulife AS

Executive Team

Henrik Bruun Andersen

CFO

Executive Team

InsuLife Investors

Notable investors and investment history

InsuLife investors
InvestorRounds
AleapAccelerator
Innovasjon NorgeGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 3, 2025

    Monthly visitors increased 303% MoM, reaching 1.4K.

  • Feb 20, 2025

    Monthly visitors increased 57% MoM.

InsuLife Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

InsuLife Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about InsuLife's valuation, stock price, and market status.

Firmographic Details

HeadquartersOslo
Employee Range15
Year Founded2020
Last FundingApr 24, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.